tetrabenazine — Medical Mutual

Initial criteria

• Patient age ≥ 18 years
• Diagnosis of Huntington’s disease confirmed by genetic testing (e.g., an expanded HTT CAG repeat sequence of at least 36)
• Medication is prescribed by or in consultation with a neurologist

Reauthorization criteria

• Response to therapy is required for continuation of therapy

Approval duration

1 year